Diabetic retinopathy (DR) is an ophthalmic complication of diabetes. In the advanced stages of DR, leaking fluid from abnormal blood vessels can cause the macula to swell, impacting sharp vision in the center of the visual field, a condition known as diabetic macular edema (DME). Several current therapies targeting vascular endothelial growth factor (VEGF) have been shown to improve visual acuity in DME patients. The most frequently used anti-VEGF agents in DME, administered via intravitreal (eye) injections, are Lucentis and Eylea—both approved for the treatment of DME—and off-label compounded Avastin. In addition to the anti-VEGF therapies, two long-acting corticosteroid implants, Ozurdex and Iluvien, were approved in 2014 for the treatment of DME. Additionally, some patients may be treated with intravitreal injections of triamcinolone. Given the competitive DME market, it is essential to understand how DME patients are currently being treated using real-world data.

Questions Answered

  • What patient share do key brands garner by line of therapy in newly diagnosed DMEpatients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DME patients?
  • How have Avastin, Eylea, Iluvien, Lucentis, and Ozurdex been integrated into the treatment algorithm?
  • What proportion of DME patients receive drug therapy within a year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
  • What percentage of DME patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with DME?

Product Description

Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.


Related Reports

Diabetic Macular Edema / Diabetic Retinopathy | Landscape & Forecast | Disease Landscape & Forecast

Patients with proliferative diabetic retinopathy (PDR) experience retinal damage that can eventually lead to debilitating vision defic...

View Details

Diabetic Macular Edema / Diabetic Retinopathy | Access & Reimbursement | Detailed, Expanded Analysis: Special Focus on Retinal Therapies: US Payer Management of the Medical Benefit

As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to i...

View Details

Diabetic Macular Edema | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key diabetic macular edema...

View Details

Diabetic Macular Edema / Diabetic Retinopathy | Special Topics | Special Topics: Biosimilar Anti-VEGF Agents (US)

The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retin...

View Details